RSS   Newsletter   Contact   Advertise with us

BIND Therapeutics appoints Andrew Hirsch as president, CEO

Staff writer | Cambridge, Mass., USA | June 23, 2015
Andrew HirschJune 23, 2015, Cambridge, Mass., USA - BIND Therapeutics, a nanomedicine company, announced that Andrew Hirsch has been appointed president and chief executive officer.
Mr. Hirsch had been serving in the role on an acting basis since March 2015.

Previosuly, Mr. Hirsch served as company's Chief Operating Officer and Chief Financial Officer since March 2014 and as Chief Financial Officer since joining the Company in July 2012. From June 2011 to May 2012, he was Vice President of Finance and Chief Financial Officer at Avila Therapeutics.

From 2002 to 2011, Mr. Hirsch served in roles of increasing responsibility during his nearly 10-year tenure at Biogen, most recently from 2010 to 2011 as Vice President, Corporate Strategy and M&A. From 2007 to 2010, Mr. Hirsch held various positions in the finance organization including leading the company’s Business Planning and Investor Relations functions.

In addition, Mr. Hirsch served as Program Executive in neurology, leading the development teams for the BG-1, Avonex and Tysabri programs. He received his M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST